U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S.2ClH.H2O
Molecular Weight 302.264
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE DIHYDROCHLORIDE

SMILES

O.Cl.Cl.CCCN[C@H]1CCC2=C(C1)SC(N)=N2

InChI

InChIKey=APVQOOKHDZVJEX-QTPLPEIMSA-N
InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H17N3S
Molecular Weight 211.327
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [EC50]
27.0 nM [EC50]
15.0 nM [EC50]
4.81 µM [IC50]
5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

8.6762881E11
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

8.6762881E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources: Page: p.740
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources: Page: p.727
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources: Page: p.128
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Disc. AE: Nausea, Hallucination...
AEs leading to
discontinuation/dose reduction:
Nausea (0.6%)
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources: Page: p.740
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources: Page: p.740
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources: Page: p.727
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources: Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources: Page: p.128
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources: Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources: Page: p.740
PubMed

PubMed

TitleDatePubMed
Role of dopamine D3 receptors in thermoregulation: a reappraisal.
2000 Jan 17
Current and emerging treatments in Parkinson's disease.
2001 Mar
Restless legs syndrome in the older adult: diagnosis and management.
2002
Two advances in the management of Parkinson disease.
2002 Aug
[Rapid-eye-movement sleep disorders in Parkinson's disease].
2002 Feb
A review of pramipexole and its clinical utility in Parkinson's disease.
2002 Feb
Pramipexole for depression.
2002 Feb
[Multiple latency test in a patient with episodes of sleep induced by pergolide].
2002 Jun 16-30
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
Restless legs syndrome augmentation and pramipexole treatment.
2002 Nov
Neuroprotection in idiopathic Parkinson's disease.
2002 Oct
Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens.
2002 Oct
Review: selegiline improves symptoms and levodopa is better than pramipexole for motor function in untreated Parkinson disease.
2002 Sep-Oct
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
2003
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.
2003
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
2003 Jul
Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.
2003 Jun
Efficacy, safety and cost of new drugs acting on the central nervous system.
2003 May
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
2003 Nov
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
2003 Oct
Current treatment options for restless legs syndrome.
2003 Oct
Clinical strategies to prevent and delay motor complications.
2003 Sep 23
Patents

Sample Use Guides

Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:14 UTC 2023
Edited
by admin
on Fri Dec 15 15:30:14 UTC 2023
Record UNII
3D867NP06J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRAMIPEXOLE DIHYDROCHLORIDE
ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
SND-919CL2Y
Code English
SND919CL2Y
Code English
SIFROL
Brand Name English
PRAMIPEXOLE HYDROCHLORIDE MONOHYDRATE
Common Name English
PRAMIPEXOLE TEVA
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
EMA EPAR   EP   MI   USP-RS   WHO-DD  
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EMA EPAR]
Common Name English
PNU-98528E
Code English
PRAMIPEXOLE DIHYDROCHLORIDE [USP MONOGRAPH]
Common Name English
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate
Systematic Name English
MIRAPEX
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE [VANDF]
Common Name English
PRAMIPEXOLE ACCORD
Brand Name English
MIRAPEXIN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [USP-RS]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE [JAN]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [USAN]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE [MART.]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EP MONOGRAPH]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE
JAN  
Common Name English
OPRYMEA
Brand Name English
Pramipexole dihydrochloride monohydrate [WHO-DD]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [ORANGE BOOK]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE
MART.  
Common Name English
DAQUIRAN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS PRAMIPEXOLE TEVA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
NCI_THESAURUS C66884
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS OPRYMEA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS DAQUIRAN (WITHDRAWN: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
NCI_THESAURUS C38149
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID1044227
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
RS_ITEM_NUM
1553859
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
RXCUI
236747
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY RxNorm
CAS
191217-81-9
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
DAILYMED
3D867NP06J
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
CHEBI
51147
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
CHEBI
51148
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
DRUG BANK
DBSALT001198
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
EVMPD
SUB25197
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
NCI_THESAURUS
C29374
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
SMS_ID
100000091470
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
USAN
KK-01
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
EVMPD
SUB12563MIG
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
PUBCHEM
166589
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
FDA UNII
3D867NP06J
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
MERCK INDEX
m9095
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY Merck Index
EVMPD
SUB04004MIG
Created by admin on Fri Dec 15 15:30:14 UTC 2023 , Edited by admin on Fri Dec 15 15:30:14 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY